Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
08:00am, Monday, 01'st Jun 2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerabilit
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, tod
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
07:05am, Monday, 04'th May 2026
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md. , May 04,
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
10:15am, Tuesday, 21'st Apr 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
08:05am, Tuesday, 07'th Apr 2026
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
04:05pm, Tuesday, 31'st Mar 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
04:05pm, Thursday, 05'th Mar 2026
BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in
NextCure Provides Business Update
07:00am, Friday, 23'rd Jan 2026
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided upd
Short Interest in NextCure, Inc. (NASDAQ:NXTC) Expands By 29.6%
01:34am, Wednesday, 31'st Dec 2025
NextCure, Inc. (NASDAQ: NXTC - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 26,706 shares, a growth
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)
02:14am, Sunday, 21'st Dec 2025
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and NextCure (NASDAQ: NXTC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two co
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
08:00am, Thursday, 20'th Nov 2025
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
08:00am, Monday, 17'th Nov 2025
BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
08:00am, Wednesday, 12'th Nov 2025
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
10:55am, Tuesday, 11'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the posi
